Welcome to the second of five episodes in our podcast series “Digital Deals in Life Sciences – What Makes Them Different?” Transactions involving digital assets are becoming an increasing focus for pharmaceutical companies. In this series, life sciences industry M&A veteran and Sterling Technology board advisor John Easton will discuss how these differ from traditional life science deals, and what both parties should look out for to increase the chances of deal success, mitigate risks, and avoid failure.
In this third episode, we consider the challenges associated with defining and valuing digital assets. How an asset is defined represents one of the key differences between traditional and digital deals; the rise of the latter asks tricky new questions of patent laws designed to handle the former, placing acquirers and targets in unchartered territory. How can they navigate it? You can also learn more by downloading our report which accompanies this podcast series.
